Latest Dendreon Stories
MIAMI BEACH, Fla., Feb.
SEATTLE, Feb. 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Tuesday, March 1, 2011 at 4:30 p.m. ET to review fourth quarter and year-end financial results.
WORCESTER, Mass., Feb. 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc.
VANCOUVER, Canada, Jan. 21, 2011 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trades found in for Oracle, Hewlett-Packard, State Street, Walt Disney, Aruba, & Dendreon.
SEATTLE, Jan. 7, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced several updates regarding the U.S. commercialization of PROVENGEÂ® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline. The Company will host a conference call at 9:00 a.m.
SEATTLE, Jan. 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Friday, January 7, 2011 at 9:00 a.m. ET to provide updates on U.S.
SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) and raised its twelve month target price from $4.40 to $6.50.
- A poem in which the author retracts something said in an earlier poem.